• DIDS in Tumor Stress Modulation: Beyond Ion Channel Blockade

  2026-05-25

  Explore how DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid) advances research on tumor cell stress, metastasis, and neuroprotection. This article uniquely integrates mechanistic insights with recent breakthroughs in the origins of metastasis.

• Isradipine (Dynacirc): Beyond Hypertension—A Precision Tool

  2026-05-24

  Explore how Isradipine (Dynacirc) enables advanced research on L-type calcium channel physiology, surpassing classic hypertension models to unravel calcium-mediated neurotoxicity and vascular smooth muscle dynamics. This article provides unique, practical insights for optimizing assay design using this high-purity research compound.

• NLRP10 Regulates Keratinocyte Survival and Barrier Function

  2026-05-23

  The reference study identifies NLRP10 as a critical regulator of epidermal homeostasis, demonstrating its reduced expression in atopic dermatitis (AD) skin and its essential role in keratinocyte survival, differentiation, and barrier integrity. These findings clarify NLRP10’s mechanistic involvement in AD pathogenesis and suggest new therapeutic targets for restoring skin barrier function.

• BIRC2 and BIRC3 Regulation by Cytokines and Glucocorticoids

  2026-05-22

  This study elucidates the differential regulation of BIRC2 and BIRC3 expression in pulmonary epithelial cells under inflammatory and glucocorticoid stimuli. Its findings reveal cytokine-driven, NF-κB-dependent induction of BIRC3, with distinct kinetics and modulation compared to BIRC2, informing future research on epithelial barrier defense and apoptosis regulation.

• Mubritinib Reveals OXPHOS Dependency in Poor Outcome AML

  2026-05-22

  Baccelli et al. (2019) identify Mubritinib as a potent inhibitor of mitochondrial complex I, selectively targeting acute myeloid leukemia (AML) subtypes with high oxidative phosphorylation (OXPHOS) activity. This work uncovers metabolic heterogeneity in AML, providing a scientific rationale for repurposing Mubritinib in chemotherapy-resistant disease.

• Desert lncRNA HIDEN Stabilizes FZD5 mRNA to Drive Endoderm D

  2026-05-21

  Lu et al. reveal that the desert lncRNA HIDEN is a pivotal regulator of human definitive endoderm differentiation by interacting with the RNA-binding protein IMP1 and stabilizing FZD5 mRNA. Their findings clarify previously underexplored roles of distal lncRNAs, linking HIDEN to WNT pathway activation and germ layer specification.

• PBS Liposomes: Precision Controls for Macrophage Depletion

  2026-05-21

  PBS Liposomes from APExBIO set the benchmark for inert, reproducible controls in macrophage depletion workflows. Their robust uptake, non-cytotoxic profile, and compatibility with advanced immunological assays help researchers distinguish true clodronate-specific effects with confidence.

• Cy3 NHS ester (non-sulfonated): Practical Labeling Guide

  2026-05-20

  Cy3 NHS ester (non-sulfonated) enables efficient labeling of proteins, peptides, and oligonucleotides for sensitive detection in biomedical imaging, especially when high signal in the orange spectrum is needed. It is unsuitable for aqueous-only protocols or applications requiring long-term storage of solutions. This article clarifies optimal handling, setup, and troubleshooting for reproducible results.

• Allosteric Degradation of Exportin 1 by SINE Compounds: Mech

  2026-05-20

  This study uncovers how SINE compounds, including selinexor, induce degradation of exportin 1 (XPO1) through an allosteric mechanism that facilitates ASB8-mediated ubiquitination. The findings broaden the paradigm of targeted protein degradation beyond traditional molecular glue and PROTAC strategies, with implications for cancer therapy and the rational design of protein regulation tools.

• Mubritinib (TAK 165): Advancing Cancer Metabolism Strategies

  2026-05-19

  This thought-leadership article dissects Mubritinib (TAK 165)'s transformation from a legacy HER2 inhibitor to a frontline mitochondrial complex I inhibitor, reframing translational oncology and virology research. Integrating mechanistic insight, experimental guidance, and competitive benchmarking—with direct reference to peer-reviewed advances in mitochondrial OXPHOS modulation—this work provides translational researchers with a roadmap for leveraging Mubritinib in disease models that demand selectivity, reproducibility, and mechanistic clarity beyond conventional HER2 signaling inhibition.

• HyperScript™ Reverse Transcriptase: Advanced Enzyme Insights

  2026-05-19

  Explore how HyperScript™ Reverse Transcriptase enables high-fidelity cDNA synthesis for qPCR from difficult RNA templates. This article provides a deep scientific analysis, integrating new assay decision frameworks and insights from recent retinal disease research.

• BHQ and SERCA: Advancing Stem Cell Mobilization Strategies

  2026-05-18

  This thought-leadership article explores how 2,5-di-tert-butylbenzene-1,4-diol (BHQ) redefines SERCA inhibition for hematopoietic stem cell mobilization. Integrating mechanistic insight, translational relevance, and strategic guidance, it details how BHQ-driven disruption of calcium homeostasis enables new research trajectories, surpassing conventional approaches and offering actionable recommendations for investigators.

• GST-Driven Resistance to Lambda-Cyhalothrin in M. usitatus:

  2026-05-18

  This study reveals that glutathione S-transferase (GST) upregulation is crucial for Megalurothrips usitatus resistance to the insecticide lambda-cyhalothrin, primarily by enhancing antioxidant defenses. Through targeted inhibition of GST using diethyl maleate, the research quantifies the functional contribution of GST to oxidative stress adaptation and resistance, offering evidence-based avenues for resistance management in pest control.

• QbD Evaluation of pH-Mediated Ribociclib Interactions in Can

  2026-05-17

  This study applies a rigorous Quality by Design (QbD) framework to determine whether acid-reducing agents alter the solubility and absorption of ribociclib, a key CDK4/6 inhibitor for breast cancer. The findings indicate that pH shifts induced by such agents do not significantly impact ribociclib’s pharmacokinetic profile, supporting clinical flexibility in co-administration and establishing a workflow for similar drug-interaction assessments.

• Repurposing Safe Drugs to Guide DNA Repair in CRISPR Editing

  2026-05-16

  This study systematically screens FDA-approved drugs to identify modulators of DNA double-strand break (DSB) repair pathways in human iPSCs. By mapping how small molecules influence NHEJ, MMEJ, and HDR outcomes, the research opens new precision strategies for genome engineering, disease modeling, and synthetic lethality in cancer.

451 records 17/31 page Previous Next First page 上5页 1617181920 下5页 Last page